Pheidippides redux: Reducing risk for acute cardiac events during marathon running

American Journal of Medicine

Volumn 125, Issue 7, 2012, Pages 630-635

  Siegel, Arthur J ^a,b,c  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aspirin prophylaxis; Cardiac arrest; Marathon running

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; GELATINASE B; INTERLEUKIN 6; VON WILLEBRAND FACTOR;

CARDIOVASCULAR RISK; DIABETES MELLITUS; HEART ARREST; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MARATHON RUNNER; NEUTROPHILIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SUDDEN DEATH; THROMBOCYTE ACTIVATION;

ASPIRIN; DEATH, SUDDEN, CARDIAC; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; RUNNING;

EID: 84862659899     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.11.008     Document Type: Review

References (73)

1. Williams H, Arnold HD. The effects of violent and prolonged muscular exercise upon the heart. Phila Med J. 1899:1233-1235.
2. Thompson PD, Venero CV. A history of medical reports on the Boston Marathon: 112 years and still running. Med Sci Sports Exerc. 2009; 41(2):257-264.
3. Currens JH, White PD. Half a century of running. Clinical, physiologic and autopsy findings in the case of Clarence DeMar ('Mr. Marathon'). N Engl J Med. 1961;265:988-993.
4. Bassler TJ. Marathon running and immunity to atherosclerosis In: Milvy P, ed. The marathon; physiological, epidemiological and psychological studies. Ann NY Acad Sci. 1977;301:579-592.
5. Albano AJ, Thompson PD, Kapur NK. Acute coronary thrombosis in Boston marathon runners. N Engl J Med. 2012;366(2):184-185.
6. Kim JH, Malhotra R, Chiampas G, et al; RACER Study Group. Cardiac arrest during long-distance running. N Engl J Med. 2012; 366(2):130-142.
7. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk for coronary heart disease; a meta-analysis. Circulation. 2011;124:789-795.
8. Whang W, Manson JE, Hu FB, et al. Physical exertion, exercise, and sudden cardiac death in women. JAMA. 2006;295(12):1399-1403.
9. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med. 2000;343(19):1355-1366.
10. Burfoot A. Heart Health. The bottom line on exercise, marathons, and heart-attack deaths. Available at: www.runnersworld.com/article/printer/1,7124, s6-241-285-12948-0,00.html.
11. Redelmeier DA, Greenwaid JA. Competing risks of mortality with marathons: retrospective analysis. BMJ. 2007;335(7633):1275-1277.
12. Pedoe DST. Marathon cardiac deaths. Sports Med. 2007;37:4-5.
13. Matthews SC, Narotsky DL, Berbholt DV, et al. Mortality among marathon runners in the United States, 2000-2009. Am J Sports Med. 2012 May 4 [Epub ahead of print].
14. Noakes TD. Heart disease in marathon runners: a review. Med Sci Sports Exerc. 1987;19(3):187-194.
15. Giri S, Thompson PD, Kierman FJ, et al. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. JAMA. 1999;282:1731-1736.
16. Burker AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA. 1999;281(10):921-926.
17. Schmermund A, Schwartz RS, Adamzik M, et al. Coronary atherosclerosis in unheralded sudden coronary death under age 50: histopathologic comparison with 'health' subjects dying out of hospital. Atherosclerosis. 2001;155(2):499-508.
18. Green LH, Cohen SI, Kurland G. Fatal myocardial infarction in marathon racing. Ann Intern Med. 1976;84(6):704-706.
19. Siegel AJ, Silverman LM, Lopez MS. Creatine kinase elevations in marathon runners: relationship to training and competition. Yale J Biol Med. 1980;53:275-279.
20. Blake JB, Larrabee RC. Observations upon long-distance runners. Boston Med Surg J. 1903;148:195-206.
21. Kratz A, Lewandrowski KB, Siegel AJ, et al. Effect of marathon running on hematologic and biochemical laboratory parameters, including cardiac markers. Am J Clin Pathol. 2002;118:856-863.
22. Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med. 2007;120:5:461.e11-461.e17.
23. Saenz AJ, Lee-Lewandrowski E, Wood MJ, et al. Measurement of a plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston Marathon. Am J Clin Pathol. 2006;126(2):1-5.
24. Siegel AJ, Stec JJ, Lipinska I, et al. Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol. 2001;88:35-37.
25. Kratz A, Wood MJ, Siegel AJ, Hiers JR, Van Cott EM. Effects of marathon running on platelet activation markers. Direct evidence for in vivo platelet activation. Am J Clin Pathol. 2006;125:296-300.
26. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31(7):777-783.
27. Arzamendi D, Benito B, Tizon-Marcos H, et al. Increase in sudden death from coronary artery disease in young adults. Am Heart J. 2011;161:574-580.
28. Kales SN, Soteriades ES, Christophi CA, Christiani DC. Emergency duties and deaths from heart disease among firefighters in the United States. N Engl J Med. 2007;356:1207-1215.
29. Mittleman MA, Mintzer D, Maclure M. Tofler GH, Sherwood JB, Muller JE. Triggering of myocardial infarction by cocaine. Circulation. 1999;99(21):2737-2741.
30. Möhlenkamp S, Schmermund A, Kröger K, et al. Coronary atherosclerosis and cardiovascular risk in masters male marathon runners. Rationale and design of the "marathon study". Herz. 2006;31(6): 575-585.
31. Möhlenkamp S, Lehmann N, Breuckmann F, et al. Running: the risk of coronary events: prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. Eur Heart J. 2008;29(15):1903-1910.
32. Scherr J, Braun S, Schustr T, et al. 71-h kinetics of high-sensitive troponin T and inflammatory markers after marathon. Med Sci Sports Exer. 2011;43(10):1819-1827.
33. Chiuve SE, Fung TT, Rexrode FM, et al. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 2011;306:62-69.
34. Sesso HD, Paffebbarger RS, Lee IM. Physical activity and coronary heart disease in men: the Harvard Alumni Health Study. Circulation. 2000;102:975-980.
35. Chomistek AK, Chiuve SE, Jensen MK, Cook NR, Rimm EB. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc. 2011;43(10):1884-1890.
36. Libby P, Ridker P. Inflammation and atherosclerosis: the role of C-reactive protein in risk assessment. Am J Med. 2004;116(6A):9S-16S.
37. Radak Z, Chung HY, Koltai E, Taylor AW, Goto S. Exercise, oxidative stress and hormesis. Ageing Res Rev. 2008;7(1):34-42.
38. Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies. Circulation. 2006;114:1863-1872.
39. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in primary prevention of cardiovascular disease. Am J Med. 1011;124:621-629.
40. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115-124. e2.
41. Thompson PD, Franklin BA, Balady GJ, et al; American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Heart Association Council on Clinical Cardiology; American College of Sports Medicine. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007;115(17):2358-2368.
42. American College of Sports Medicine, American Heart Association. Exercise and acute cardiovascular events: placing the risks into perspective. Med Sci Sports Exerc. 2007;39(5):886-897.
43. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011:124(22):2458- 2473.
44. Tsang JLY, Mendelsohn A, Tan MKK, et al. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence based medical therapy. Am J Cardiol. 2008;102:1142-1145.
45. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010; 121(24):2694-2701.
46. Sullivan J. Is marathon running dangerous? October 19, 2009. Available at: http://www.findingdulcinea.com/news/sports/2009/oct/Is-Marathon-Running- Dangerous.html.
47. Maharam LG, Siegel AJ, Siegel S, Adams B, Pujol P, Lourega de Menezes P. IMMDA's health recommendations for runners & walkers. Approved by the International Marathon Medical Directors Association (IMMDA) Body, March 20, 2010, Barcelona, Spain. Available at: http://www.aimsassociation.org/guidelines- fluid-replacemen.html. Accessed April 1, 2010.
48. Bavry AA, Khaliq A, Gong Y, Handberg EM, Cooper-Dehaoff RM, Pepine CJ. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med. 2011;124(7):614-620.
49. Maharam L. How can I avoid sudden death while running? Available at: http://www.nydailynews.com/sports/more-sports/2011/10/03/2011-10-03-how-can-i- avoid-sudden-death-while-running-education-is-the-key-for-longdi stance.html.
50. Hinkel D. Firefighter and father of two who died was a veteran marathoner. Chicago Tribune, Oct 9, 2011. Available at: http://www. chicagotribune.com.
51. Running USA Inc. Available at: http://www.runningUSA.com.
52. Boston Athletic Association. Available at: http://www.baa.org.
53. BBC News. What's happened to Sir Ranulph Fiennes' body? Available at: http://news.bbc.co.uk/go/pr/fr/-/2/hi/uk-news/magazine/3224745.stm.
54. Feldman TE, Fisher WG, Silver RL. A case-based approach to improved strategies to reduce risk for SCA Post-PCI. Available at: http://www.medscape. org/viewarticle/749615. Accessed September 26, 2011.
55. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:375-385.
56. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol. 2007;99(5):732-738.
57. Ridker PM, Danielson E, Fonseca F, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
58. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Association between C reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378(9791):684-692.
59. Lenz TL. Are physically active individuals taking statins at increased risk for myopathy? Am J Lifestyle Med. 2009;3(4):287-289.
60. Yusuf S, Islam S, Chow CK, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-1243.
61. Kumar A, Kar S, Fay WP. Thrombosis, physical activity, and acute coronary syndromes. J Appl Physiol. 2011;111(2):599-605.
62. Berent R, Auer J, Franklin B, Schmid P, von Duvillard SP. Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. Am J Cardiol. 2011;108:644-650.
63. Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132:711-714.
64. Hew-Butler T, Ayus JC, Kipps C, et al. Consensus Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med. 2008;18(2):111-121.
65. Siegel AJ. Exercise-associated hyponatremia: role of cytokines. Am J Med. 2006;119(1):S74-S78.
66. Swart RM, Hoorn EJ, Betjes MG, Zietse R. Hyponatremia and inflammation: the emerging role of interleukin-6 in osmoregulation. Nephron Physiol. 2011;118:45-51.
67. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Chest. 2012;14(2 Suppl):7s-47s.
68. Pederson JO, Heitmann BL, Schnohr P, Gronback M. The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality. Eur Heart J. 2008;29:204-212.
69. Monagas M, Khan N, Andres-Lacueva C, et al. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am J Clin Nutr. 2009;90(5): 1144-1150.
70. Bultrago-Lopez A, Sanderson J, Johnson L, et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ. 2011;343:d4488.
71. Dwyer N, Kanani R. Left main coronary artery thrombosis. N Engl J Med. 2012;366(14):e21.
72. Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden death in the general population. Circulation. 2011;124:672-681.
73. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2012;125:1058-1072.